Literature DB >> 9927431

Destruction of Myc by ubiquitin-mediated proteolysis: cancer-associated and transforming mutations stabilize Myc.

S E Salghetti1, S Y Kim, W P Tansey.   

Abstract

The human proto-oncogene c-myc encodes a highly unstable transcription factor that promotes cell proliferation. Although the extreme instability of Myc plays an important role in preventing its accumulation in normal cells, little is known about how Myc is targeted for rapid destruction. Here, we have investigated mechanisms regulating the stability of Myc. We show that Myc is destroyed by ubiquitin-mediated proteolysis, and define two elements in Myc that oppositely regulate its stability: a transcriptional activation domain that promotes Myc destruction, and a region required for association with the POZ domain protein Miz-1 that stabilizes Myc. We also show that Myc is stabilized by cancer-associated and transforming mutations within its transcriptional activation domain. Our data reveal a complex network of interactions regulating Myc destruction, and imply that enhanced protein stability contributes to oncogenic transformation by mutant Myc proteins.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9927431      PMCID: PMC1171164          DOI: 10.1093/emboj/18.3.717

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  50 in total

1.  An amino-terminal c-myc domain required for neoplastic transformation activates transcription.

Authors:  G J Kato; J Barrett; M Villa-Garcia; C V Dang
Journal:  Mol Cell Biol       Date:  1990-11       Impact factor: 4.272

Review 2.  Control of c-myc regulation in normal and neoplastic cells.

Authors:  C A Spencer; M Groudine
Journal:  Adv Cancer Res       Date:  1991       Impact factor: 6.242

3.  Promoter-selective activation domains in Oct-1 and Oct-2 direct differential activation of an snRNA and mRNA promoter.

Authors:  M Tanaka; J S Lai; W Herr
Journal:  Cell       Date:  1992-02-21       Impact factor: 41.582

4.  Degradation of nuclear oncoproteins by the ubiquitin system in vitro.

Authors:  A Ciechanover; J A DiGiuseppe; B Bercovich; A Orian; J D Richter; A L Schwartz; G M Brodeur
Journal:  Proc Natl Acad Sci U S A       Date:  1991-01-01       Impact factor: 11.205

5.  Differential transcriptional activation by Oct-1 and Oct-2: interdependent activation domains induce Oct-2 phosphorylation.

Authors:  M Tanaka; W Herr
Journal:  Cell       Date:  1990-02-09       Impact factor: 41.582

6.  Rapid and efficient site-specific mutagenesis without phenotypic selection.

Authors:  T A Kunkel; J D Roberts; R A Zakour
Journal:  Methods Enzymol       Date:  1987       Impact factor: 1.600

7.  Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc.

Authors:  E M Blackwood; R N Eisenman
Journal:  Science       Date:  1991-03-08       Impact factor: 47.728

8.  Transcriptional activation by the human c-Myc oncoprotein in yeast requires interaction with Max.

Authors:  B Amati; S Dalton; M W Brooks; T D Littlewood; G I Evan; H Land
Journal:  Nature       Date:  1992-10-01       Impact factor: 49.962

9.  Targeted degradation of c-Fos, but not v-Fos, by a phosphorylation-dependent signal on c-Jun.

Authors:  A G Papavassiliou; M Treier; C Chavrier; D Bohmann
Journal:  Science       Date:  1992-12-18       Impact factor: 47.728

10.  A phosphorylation site located in the NH2-terminal domain of c-Myc increases transactivation of gene expression.

Authors:  A Seth; E Alvarez; S Gupta; R J Davis
Journal:  J Biol Chem       Date:  1991-12-15       Impact factor: 5.157

View more
  149 in total

1.  c-Myc proteolysis by the ubiquitin-proteasome pathway: stabilization of c-Myc in Burkitt's lymphoma cells.

Authors:  M A Gregory; S R Hann
Journal:  Mol Cell Biol       Date:  2000-04       Impact factor: 4.272

2.  The c-Myc transactivation domain is a direct modulator of apoptotic versus proliferative signals.

Authors:  D W Chang; G F Claassen; S R Hann; M D Cole
Journal:  Mol Cell Biol       Date:  2000-06       Impact factor: 4.272

Review 3.  How cells use proteolysis to control their growth.

Authors:  W P Tansey
Journal:  Mol Med       Date:  1999-12       Impact factor: 6.354

4.  HAM: a new epitope-tag for in vivo protein labeling.

Authors:  A Herbst; W P Tansey
Journal:  Mol Biol Rep       Date:  2000       Impact factor: 2.316

5.  The corepressor mSin3a interacts with the proline-rich domain of p53 and protects p53 from proteasome-mediated degradation.

Authors:  J T Zilfou; W H Hoffman; M Sank; D L George; M Murphy
Journal:  Mol Cell Biol       Date:  2001-06       Impact factor: 4.272

6.  Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability.

Authors:  R Sears; F Nuckolls; E Haura; Y Taya; K Tamai; J R Nevins
Journal:  Genes Dev       Date:  2000-10-01       Impact factor: 11.361

7.  In vivo interference with Skp1 function leads to genetic instability and neoplastic transformation.

Authors:  Roberto Piva; Jian Liu; Roberto Chiarle; Antonello Podda; Michele Pagano; Giorgio Inghirami
Journal:  Mol Cell Biol       Date:  2002-12       Impact factor: 4.272

8.  Phosphorylation by p38MAPK and recruitment of SUG-1 are required for RA-induced RAR gamma degradation and transactivation.

Authors:  Maurizio Giannì; Annie Bauer; Enrico Garattini; Pierre Chambon; Cécile Rochette-Egly
Journal:  EMBO J       Date:  2002-07-15       Impact factor: 11.598

9.  Early mitotic degradation of the homeoprotein HOXC10 is potentially linked to cell cycle progression.

Authors:  Davide Gabellini; Ivan N Colaluca; Hartmut C Vodermaier; Giuseppe Biamonti; Mauro Giacca; Arturo Falaschi; Silvano Riva; Fiorenzo A Peverali
Journal:  EMBO J       Date:  2003-07-15       Impact factor: 11.598

10.  Phosphorylation of progesterone receptor serine 400 mediates ligand-independent transcriptional activity in response to activation of cyclin-dependent protein kinase 2.

Authors:  Lisa K Pierson-Mullany; Carol A Lange
Journal:  Mol Cell Biol       Date:  2004-12       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.